# Clinical Trials Data ALK - Document 5

# A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

## Clinical Trial: https://clinicaltrials.gov/study/NCT01994057

"eligibilityCriteria": "Inclusion Criteria:\n\nThe main patient entry criteria included: age\u2265 18 years ; histologically and cytologically proved NSCLC; Eastern cooperative oncology group performance status (ECOG PS)\u22642; adequate hematological , renal, and hepatic functions. Exclusion Criteria:\n\nuncontrolled systemic disease ,any evidence of clinically active interstitial lung diseases, and other chemotherapy at the time of inclusion. The protocol was approved by the Ethical Committee of Cancer Center of Sun Yat-Sen University (CCSU), and written informed consent was obtained form each patient.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "locally advanced or metastatic NSCLC (non-small cell lung cancer) patients; administrated with gefitinib,erlotinib .",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
This trial is for NSCLC patients treated with gefitinib or erlotinib. These drugs are typically used in patients with \*EGFR\* mutations, \*not\* ALK mutations. While the eligibility criteria don't explicitly exclude patients with ALK mutations, the study population description strongly suggests this trial isn't designed for them. An ALK-positive patient would likely be directed to a trial investigating ALK inhibitors like crizotinib or alectinib. Therefore, a patient with an ALK mutation would likely \*not\* be eligible for this particular trial.